Bayir Yasin, Un Harun, Cadirci Elif, Akpinar Erol, Diyarbakir Busra, Calik Ilknur, Halici Zekai
Faculty of Pharmacy, Department of Biochemistry, Ataturk University Campus, 25240, Erzurum, Turkey.
Faculty of Pharmacy, Department of Biochemistry, Agri Ibrahim Cecen University Campus 04100, Agri, Turkey.
An Acad Bras Cienc. 2019;91(1):e20180106. doi: 10.1590/0001-3765201820180106. Epub 2018 Dec 17.
Our aim is to investigate the potentially preventive effects of Aliskiren in a carrageenan-induced lung pleurisy model and to compare the standard anti-inflammatory agents, indomethacin and dexamethasone. The pleurisy model was induced through the injection of carrageenan (0.2 ml-%2) into the pleural cavity. After the experiment, serum and lung tissues were collected and biochemical, molecular and pathological examinations were performed. In our study, pleural inflammation decreased superoxide dismutase activity and the glutathione level and increased the malondialdehyde level in the lung of rats, while Aliskiren increased the superoxide dismutase activity and glutathione level and decreased the malondialdehyde level. In addition, carrageenan-induced pleurisy caused a significant increase in pro-inflammatory cytokines mRNA expressions (TNF-α, IL-1β, and NF-KB), while Aliskiren administration decreased their expressions as well as the standard treatments, indomethacin and dexamethasone, did. Aliskiren administration at the 200 mg/kg dose protected the lungs in the pathological evaluation, especially against inflammatory cell infiltration and edematous lesions. It appears that Aliskiren protects the lung from carrageenan-induced pleurisy damage by regulating inflammation and antioxidant-oxidant balance via Renin Angiotensin Aldosterone System inhibition.
我们的目的是在角叉菜胶诱导的肺胸膜炎模型中研究阿利吉仑的潜在预防作用，并与标准抗炎药吲哚美辛和地塞米松进行比较。通过向胸腔注射角叉菜胶（0.2 ml-2%）诱导胸膜炎模型。实验结束后，收集血清和肺组织，并进行生化、分子和病理检查。在我们的研究中，胸膜炎炎症降低了大鼠肺中超氧化物歧化酶活性和谷胱甘肽水平，并增加了丙二醛水平，而阿利吉仑增加了超氧化物歧化酶活性和谷胱甘肽水平，并降低了丙二醛水平。此外，角叉菜胶诱导的胸膜炎导致促炎细胞因子mRNA表达（TNF-α、IL-1β和NF-κB）显著增加，而阿利吉仑给药降低了它们的表达，标准治疗药物吲哚美辛和地塞米松也有同样的效果。在病理评估中，200 mg/kg剂量的阿利吉仑给药对肺起到了保护作用，尤其是对抗炎性细胞浸润和水肿性病变。阿利吉仑似乎通过抑制肾素-血管紧张素-醛固酮系统调节炎症和抗氧化-氧化平衡，从而保护肺免受角叉菜胶诱导的胸膜炎损伤。
